- Full year 2025 Revenues of
$33.3 million , up 71% YoY - Full year 2025 Adjusted EBITDA of $4.1 million, up 81% YoY
Financial Highlights for the Full Year 2025 and Fourth Quarter of 2025:
- Revenues. Full year 2025 revenues were
$33.3 million , up 71% year over year ("YoY"). Q4 revenues were$7.5 million , up 53% YoY. - Adjusted EBITDA. Full year 2025 Adjusted EBITDA was
$4.1 million , up 81% YoY, Q4 Adjusted EBITDA of$0.3 million compared to prior year Q4 Adjusted EBITDA of$0.5 million . - Net Income. Full year 2025 net income was
$1.3 million , up 91% YoY, Q4 net loss of$0.3 million compared to prior year Q4 net loss of$0.1 million . - Billed Enrolled Employees. The number of billed enrolled employees (EEs) was 22,515 as of
December 31, 2025 , up 23% YoY. - Distribution. The number of Brokers, Third-party Administrator ("TPAs") and Agencies expanded to 858 partners as of December 31, 2025, up 34% YoY.
- Cash. Cash balance was $7.7 million as of December 31, 2025.
Revenue Outlook
The Company expects continued growth driven by expanding engagement across its distribution network and the full deployment of new features launched in
CEO Commentary
"In the first half of 2026, we expect to complete market testing of our Three-Year Rate stabilization program, designed to provide cost stability and predictability for eligible employer groups. We also plan to initiate beta testing of a new data-driven solution that integrates physiological data and claims data to generate actionable value insights. Together, these initiatives reflect our strategy of layering incremental, high-value services onto an already commercialized and scalable platform to drive durable growth and increasing operating leverage."
Key Developments in Q1 2026
- Engaged
Amazon Web Services (AWS) Advanced Tier Services Partner Ciklum to accelerate development ofHealth In Tech's AI-Driven InsurTech platform.
- Appointed former SAP and IBM executive
Sri Rajagopalan as Chief Technology Officer to advance AI-driven Enterprise-Grade platform growth.
- Appointed five-time founder
Zain Hasan as Chief Growth Officer to accelerate revenue growth and scale distribution.
- Introduced 100+ pre-configured stop-loss self-funded healthcare plans for employers, streamlining the renewal process and reducing cycle times.
- Hosted the inaugural independent hitDavos InsurTech Summit during World Economic Forum Week 2026, driving brand visibility and global leadership engagement across the government, technology, healthcare, and finance sectors.
Conference Call Details
A live audio webcast will be available via the Investor Relations page of
Non-GAAP Financial Information
This release presents Adjusted EBITDA, a non-GAAP financial metric, which is provided as a complement to the results provided in accordance with accounting principles generally accepted in
Use of Forward-Looking Statements
Certain statements in this press release are forward-looking statements for purposes of the safe harbor provisions under the
About
Consolidated Statements of Operations | |||||||||||
Three Months Ended | Fiscal Year Ended | ||||||||||
2025 | 2024 | 2025 | 2024 | ||||||||
Revenues | |||||||||||
Revenues from underwriting modeling | |||||||||||
Revenues from fees | 6,476,204 | 3,207,484 | 26,462,966 | 12,841,635 | |||||||
SMR | 6,476,204 | 2,470,284 | 26,462,966 | 9,849,300 | |||||||
HI Card | - | 737,200 | - | 2,992,335 | |||||||
Total revenues | 7,508,585 | 4,904,564 | 33,327,511 | 19,490,906 | |||||||
Cost of revenues | 3,379,942 | 1,107,173 | 12,389,783 | 4,051,439 | |||||||
Gross profit | 4,128,643 | 3,797,391 | 20,937,728 | 15,439,467 | |||||||
Operating expenses | |||||||||||
Sales and marketing expenses | 906,206 | 632,060 | 4,185,766 | 3,158,257 | |||||||
General and administrative expenses | 3,180,137 | 2,848,014 | 13,654,262 | 8,477,407 | |||||||
Research and development expenses | 213,113 | 633,653 | 1,569,262 | 2,813,899 | |||||||
Total operating expenses | 4,299,456 | 4,113,727 | 19,409,290 | 14,449,563 | |||||||
Other income (expense): | |||||||||||
Interest income | 104,659 | 28,774 | 409,922 | 122,885 | |||||||
Interest expenses | - | - | - | (495,000) | |||||||
Other income | - | 114,055 | 118,399 | 271,211 | |||||||
Other expense | (377,587) | 62,759 | (382,587) | - | |||||||
Total other income (expense), net | (272,928) | 205,588 | 145,734 | (100,904) | |||||||
Income (loss) before income tax | |||||||||||
Provision for income taxes | 141,184 | (33,404) | (395,330) | (218,523) | |||||||
Net income (loss) | |||||||||||
Net income per share | |||||||||||
Basic | |||||||||||
Diluted | |||||||||||
Weighted average common stocks | |||||||||||
Basic | 56,908,999 | 52,047,723 | 55,843,821 | 51,839,329 | |||||||
Diluted | 58,635,562 | 54,662,931 | 57,742,798 | 53,662,677 | |||||||
Consolidated Balance Sheets | ||||||
Assets | ||||||
Current assets | ||||||
Cash and cash equivalents | ||||||
Accounts receivable, net | 756,288 | 1,647,103 | ||||
Loans receivable, net | 815,995 | - | ||||
Other receivables, net | 3,467,814 | 500,252 | ||||
Deferred offering costs | 170,977 | - | ||||
Prepaid expenses and other current assets | 3,280,148 | 787,161 | ||||
Total current assets | 16,160,976 | 10,783,764 | ||||
Non-current assets | ||||||
Software | 6,530,894 | 3,962,461 | ||||
Loans receivable, net | - | 815,995 | ||||
Operating lease - right of use assets | 139,940 | 206,269 | ||||
Long-term prepaid expenses | 258,151 | - | ||||
Total non-current assets | 6,928,985 | 4,984,725 | ||||
Total assets | ||||||
Liabilities and stockholders' equity | ||||||
Current liabilities | ||||||
Accounts payable and accrued expenses | ||||||
Income taxes payable | - | 205,253 | ||||
Operating lease liabilities - current | 76,195 | 66,881 | ||||
Other current liability | 891,598 | - | ||||
Total current liabilities | 5,156,604 | 2,130,974 | ||||
Non-current liabilities | ||||||
Deferred tax liabilities | 757,675 | 328,676 | ||||
Operating lease liabilities - non-current | 63,617 | 139,811 | ||||
Total non-current liabilities | 821,292 | 468,487 | ||||
Total liabilities | 5,977,896 | 2,599,461 | ||||
Stockholders' equity | ||||||
Common stock, | 46,006 | 42,915 | ||||
Common stock, | 11,700 | 11,700 | ||||
Additional paid-in capital | 11,834,121 | 9,173,017 | ||||
Retained earnings | 5,220,238 | 3,941,396 | ||||
Total stockholders' equity | 17,112,065 | 13,169,028 | ||||
Total liabilities and stockholders' equity | ||||||
Consolidated Statements of Cash Flows | |||||
Fiscal Year Ended | |||||
2025 | 2024 | ||||
CASH FLOWS FROM OPERATING ACTIVITIES: | |||||
Net income | |||||
Adjustments to reconcile net income to net cash provided by | |||||
Bad debt expense (recovery) | (16,234) | 1,878 | |||
Amortization expense | 900,577 | 541,141 | |||
Provision for refund liability | 3,891,598 | - | |||
Provision for credit losses on other receivables | 377,587 | - | |||
Deferred tax expenses (benefits) | 428,999 | (93,304) | |||
Amortization of debt discount | - | 495,000 | |||
Interest income | (64,000) | (63,996) | |||
Stock-based compensation expense | 1,570,419 | 468,489 | |||
Changes in operating assets and liabilities: | |||||
Accounts receivable | 907,049 | 586,685 | |||
Other receivables | (3,345,149) | 1,180,848 | |||
Prepaid expenses and other assets | (1,948,184) | (514,242) | |||
Operating lease right of use assets and liabilities, net | (551) | 1,889 | |||
Accounts payable and accrued expenses | 2,358,113 | (851,963) | |||
Income taxes payable | (205,253) | (246,693) | |||
Other current liabilities | (3,000,000) | - | |||
Net cash provided by operating activities | 3,133,813 | 2,176,209 | |||
CASH FLOWS FROM INVESTING ACTIVITIES: | |||||
Development of software | (3,189,921) | (900,755) | |||
Interest received from loans receivable | 64,000 | 64,000 | |||
Net cash used in investing activities | (3,125,921) | (836,755) | |||
CASH FLOWS FROM FINANCING ACTIVITIES: | |||||
Proceeds from issuance of common stock in connection with | - | 8,214,000 | |||
Proceeds from stock option exercises | 23,430 | - | |||
Payments of deferred offering costs | (210,816) | (1,975,556) | |||
Repayments of notes payable | - | (2,145,000) | |||
Net cash provided by (used in) financing activities | (187,386) | 4,093,444 | |||
Increase (decrease) in cash and cash equivalents | (179,494) | 5,432,898 | |||
Cash and cash equivalents, beginning of year | 7,849,248 | 2,416,350 | |||
Cash and cash equivalents, end of year | 7,669,754 | 7,849,248 | |||
Supplemental disclosures of cash flow information: | |||||
Cash paid for interest | $- | $- | |||
Cash paid for income taxes | |||||
Summary of noncash investing and financing activities: | |||||
Accrued deferred offering costs included in accounts | $- | ||||
Accrued development of software included in accounts | |||||
Reclassification of deferred offering costs to additional paid- | $- | ||||
Stock-based compensation capitalized for software | $- | ||||
Reconciliation of GAAP (Net Income) to Non-GAAP Financial Measure (Adjusted EBITDA) | ||||||||
Three Months Ended | Fiscal Year Ended | |||||||
2025 | 2024 | 2025 | 2024 | |||||
Net income | (302,557) | (144,152) | 1,278,842 | 670,477 | ||||
Interest (income) expenses | (104,659) | (28,774) | (409,922) | 372,115 | ||||
Amortization expense | 410,630 | 135,983 | 900,577 | 541,141 | ||||
Income tax expense | (141,184) | 33,404 | 395,330 | 218,523 | ||||
Stock-based compensation expense | 76,733 | 468,489 | 1,570,419 | 468,489 | ||||
Provision for credit losses on other | 377,587 | - | 377,587 | - | ||||
Total net adjustments | 619,107 | 609,102 | 2,833,991 | 1,600,268 | ||||
Adjusted EBITDA | 316,550 | 464,950 | 4,112,833 | 2,270,745 | ||||
Investor Contact:
Health In Tech Investor Relations
ir@healthintech.com
The Equity Group
T: (303) 953-9878
kahl@theequitygroup.com
dsullivan@theequitygroup.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/health-in-tech-announces-fourth-quarter-and-full-year-2025-financial-results-302725203.html
SOURCE